Drug Trial Radar · NCT04817618
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Jul 28, 2021
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Conditions
- C3G
Interventions
PlaceboDrug
Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
iptacopanDrug
iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adult cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)Time frame: 6 months (double-blind)
- Adolescent cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)Time frame: 6 months (double-blind)
- Change from baseline in log-transformed UPCR at the 12-month visit (both study treatment arms).Time frame: 12 months (double-blind and open-label)
- Change in log-transformed UPCR from the 6-month visit to the 12-month visit in the placebo armTime frame: From month 6 to month 12 (open-label)
Locations
88 sites in 19 countries. Site status is shown where the registry gives one.
Childrens Hospital Colorado
Aurora, Colorado · Recruiting
Nicklaus Childrens Hospital
Miami, Florida · Recruiting
Georgia Nephrology Research Inst
Lawrenceville, Georgia · Completed
IN University School of Med
Indianapolis, Indiana · Withdrawn
University of Iowa Health Care
Iowa City, Iowa · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Withdrawn
Brigham and Womens Hosp Harvard Med School
Boston, Massachusetts · Withdrawn
Hackensack Uni Medical Center
Hackensack, New Jersey · Withdrawn
Albany Medical Center
Albany, New York · Withdrawn
Col Uni Med Center New York Presby
New York, New York · Completed
Baylor Scott and White Research
Temple, Texas · Withdrawn
University of Wisconsin
Madison, Wisconsin · Withdrawn
Novartis Investigative Site
Buenos Aires, Argentina · Completed
Novartis Investigative Site
CABA, Argentina · Withdrawn
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Withdrawn
Novartis Investigative Site
Edegem, Belgium · Withdrawn
Novartis Investigative Site
Leuven, Belgium · Withdrawn
Novartis Investigative Site
Salvador, Brazil · Withdrawn
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Withdrawn
Novartis Investigative Site
Recife, Pernambuco, Brazil · Recruiting
Novartis Investigative Site
Passo Fundo, Rio Grande do Sul, Brazil · Withdrawn
Novartis Investigative Site
Joinville, Santa Catarina, Brazil · Withdrawn
Novartis Investigative Site
Santo André, São Paulo, Brazil · Withdrawn
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Withdrawn
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Completed
Novartis Investigative Site
Toronto, Ontario, Canada · Completed
Novartis Investigative Site
Montreal, Quebec, Canada · Withdrawn
Novartis Investigative Site
Beijing, China · Active not recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Active not recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China · Active not recruiting
Novartis Investigative Site
Wuhan, Hubei, China · Withdrawn
Novartis Investigative Site
Prague, Czechia · Completed
Novartis Investigative Site
Lille, France · Completed
Novartis Investigative Site
Marseille, France · Withdrawn
Novartis Investigative Site
Montpellier, France · Withdrawn
Novartis Investigative Site
Paris, France · Completed
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.